Clinical Trials Logo

Filter by:
NCT ID: NCT00627640 Completed - Clinical trials for Idiopathic Parkinson's Disease

Safinamide in Idiopathic Parkinson's Disease (IPD) With Motor Fluctuations, as add-on to Levodopa

SETTLE
Start date: February 2009
Phase: Phase 3
Study type: Interventional

Parkinson's Disease is a major neurodegenerative disorder in which there is a progressive loss of dopamine-containing neurons. The understanding that PD is a syndrome of dopamine (DA) deficiency led to the introduction in the clinical practice of L-dopa, a precursor of DA that crosses the blood brain barrier, and also to the use of selective inhibitors of MAO-B, the major DA metabolising enzyme in man. Safinamide is an inhibitor of MAO-B. This is a phase III trial to evaluate the efficacy and safety of safinamide (50 and 100 mg p.o. q.a.m.) compared to placebo as add-on therapy to a stable dose to levodopa in subjects with advance idiopathic Parkinson's Disease. The principal efficacy measure is the increase in mean daily "on" time during the 18-hr diary recording period.

NCT ID: NCT00624338 Completed - Clinical trials for Lupus Erythematosus, Systemic

Atacicept Phase 2/3 in Generalized Systemic Lupus Erythematosus (APRIL-SLE)

APRIL-SLE
Start date: January 2008
Phase: Phase 2/Phase 3
Study type: Interventional

This study is to evaluate the efficacy and safety of atacicept compared to placebo in preventing new flares in subjects with systemic lupus erythematosus (SLE) and to confirm the optimal dose of atacicept for treatment of subjects with SLE and gain information on the effect of atacicept on markers specific to its mechanism of action (MoA) and their correlation to disease activity/progression. Study medication will be administered through subcutaneous (under the skin) injections, beginning with twice weekly injections for the first 4 weeks, followed by once weekly doses for 48 weeks. Following the last treatment, a safety follow-up period of 24 weeks will be conducted.

NCT ID: NCT00622648 Completed - Acute Illness Clinical Trials

Study to Evaluate the Mortality Reduction of Enoxaparin in Hospitalized Acutely Ill Medical Receiving Enoxaparin

LIFENOX
Start date: January 2008
Phase: Phase 4
Study type: Interventional

The primary objective: - To demonstrate in patients hospitalized for an acute medical illness that enoxaparin with Graduated Elastic Stockings is superior to enoxaparin-placebo with Graduated Elastic Stockings on overall mortality at day 30 after randomization. The secondary objective: - To compare, in patients hospitalized for an acute medical illness, enoxaparin with Graduated Elastic Stockings versus enoxaparin placebo with Graduated Elastic Stockings on overall mortality at day 90 after randomization. - To evaluate the safety of enoxaparin VTE prophylaxis in patients hospitalized for acute medical illness with respect to major hemorrhage, total bleedings, heparin induced thrombocytopenia, adverse events and serious adverse events .

NCT ID: NCT00621504 Completed - Bacterial Pneumonia Clinical Trials

Comparative Study of Ceftaroline vs. Ceftriaxone in Adult Subjects With Community-Acquired Pneumonia

CAP
Start date: January 2008
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine whether ceftaroline is effective and safe in the treatment of Community-Acquired Pneumonia

NCT ID: NCT00621140 Completed - Clinical trials for Diabetes Mellitus, Type 2

Efficacy and Safety of BI 1356 (Linagliptin) Versus Placebo in Type 2 Diabetic Patients With Insufficient Glycemic Control

Start date: February 2008
Phase: Phase 3
Study type: Interventional

To investigate efficacy, safety and tolerability of BI 1356 versus placebo

NCT ID: NCT00617981 Completed - Clinical trials for Hepatocellular Carcinoma

Phase 3 Study of ThermoDox With Radiofrequency Ablation (RFA) in Treatment of Hepatocellular Carcinoma (HCC)

Start date: May 2008
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine whether ThermoDox, a thermally sensitive liposomal doxorubicin, is effective in the treatment of non-resectable hepatocellular carcinoma when used in conjunction with radiofrequency ablation (RFA).

NCT ID: NCT00611026 Completed - Overactive Bladder Clinical Trials

Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine Extended Release(ER)in Patients With Overactive Bladder.

Start date: February 2008
Phase: Phase 3
Study type: Interventional

To evaluate the efficacy and safety of fesoterodine in comparison to tolterodine and placebo for overactive bladder

NCT ID: NCT00605111 Completed - Clinical trials for Diabetes Mellitus, Type 2

Efficacy and Safety of Biphasic Insulin Aspart 30 in Subjects With Type 2 Diabetes

Start date: December 2003
Phase: Phase 4
Study type: Interventional

This trial is conducted in Asia. The aim of this trial is to investigate the efficacy and safety of biphasic insulin aspart 30 as start insulin in subjects with type 2 diabetes failing OAD therapy.

NCT ID: NCT00601523 Completed - Parkinson Disease Clinical Trials

Long-term Safety Study of Open-label Pramipexole Extended Release (ER) in Patients With Early Parkinson´s Disease (PD).

Start date: January 2008
Phase: Phase 3
Study type: Interventional

The general aim of this study is to obtain long-term safety and tolerability data on pramipexole ER, in daily doses from 0.375mg to 4.5mg once daily (q.d), in patients who have previously completed a pramipexole double-blind study in early PD (248.524(NCT00479401) or 248.636(NCT00558025) trial).

NCT ID: NCT00600626 Completed - Clinical trials for Diabetes Mellitus, Type 2

Basal Bolus of Insulin Aspart Including Insulin NPH and Biphasic Insulin Aspart in Type 2 Diabetes

Start date: January 2004
Phase: Phase 3
Study type: Interventional

This trial is conducted in Europe and Asia. The aim of this trial is to compare basal bolus treatment with insulin aspart and insulin NPH to biphasic insulin aspart treatment on blood glucose control in type 2 diabetes.